PALISADE BIO, INC.
About PALISADE BIO, INC.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$16.8M
- Total assets
- $134.3M
- Market cap
- $302.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $18.1M
- Operating income
- -$18.1M
- Income tax
- $0
- Net income
- -$16.8M
- EPS (basic)
- $-0.30
- EPS (diluted)
- $-0.30
Balance sheet
- Total assets
- $134.3M
- Current assets
- $134.2M
- Total liabilities
- $5.0M
- Current liabilities
- $4.6M
- Shareholders’ equity
- $129.4M
Cash flow
- Operating cash flow
- -$10.8M
- Investing cash flow
- -$123.6M
- Financing cash flow
- $134.4M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $302.4M
- EPS (diluted)
- $-0.3
- Shares outstanding
- 173.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 28, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $16.8M in FY2024.
- Trading 38% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PALISADE BIO, INC..
Write a review
News about PALISADE BIO, INC.
News & sentiment via Polygon.io
